Xvivo Perfusion ABXVIPF -1.32%91 Graham Number is $3.59 as of Mar. 2026, which is 72% below its 10-year median of 12.84. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $42.07 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 400 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks worse than 95.25% on this metric.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
As of today (2026-06-26), the stock price of Xvivo Perfusion AB is $29.0011. Xvivo Perfusion AB's graham number for the quarter that ended in Mar. 2026 was $3.59. Therefore, Xvivo Perfusion AB's Price to Graham Number ratio for today is 8.08.
The historical rank and industry rank for Xvivo Perfusion AB's Graham Number or its related term are showing as below:
XVIPF'
s Price-to-Graham-Number Range Over the Past 10 Years
Min: 6.01 Med: 12.84 Max: 70.19
Current: 7.55
During the past 13 years, the highest Price to Graham Number ratio of Xvivo Perfusion AB was 70.19. The lowest was 6.01. And the median was 12.84.
XVIPF's Price-to-Graham-Number is ranked worse than 95.25% of 400
companies
in the Medical Devices & Instruments industry
Industry Median: 1.755
vs XVIPF: 7.55
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
Xvivo Perfusion AB (OTCPK:XVIPF) Graham Number Explanation
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
Xvivo Perfusion AB's Price to Graham number Ratio for today is calculated as
Price to Graham number
=
Share Price (Today)
/
Graham number (Q: Mar. 2026 )
=
29.0011
/
3.59
=
8.08
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
Xvivo Perfusion AB Graham Number Related Terms
Xvivo Perfusion AB Graham Number Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's Graham Number can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Xvivo Perfusion AB's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB Price-to-Graham-Number vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's Price-to-Graham-Number falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB (XVIPF) has a Graham Number of $3.59 as of Mar. 2026. The Graham Number values a company based on its per-share earnings and book value. View historical data on Xvivo Perfusion AB and its competitors. This is 72% below median its historical median of 12.84. Over the past decade, Xvivo Perfusion AB's Graham Number has ranged from 6.01 to 70.19. According to the industry distribution chart, Xvivo Perfusion AB ranks #381 out of 400 companies in the Medical Devices & Instruments industry, placing it in the top 95.2%.
Is Xvivo Perfusion AB's Graham Number too high?
Xvivo Perfusion AB's current Graham Number of $3.59 is 72% below median its 10-year median of 12.84. Over the past 10 years, this metric has ranged from a low of 6.01 to a high of 70.19. The Medical Devices & Instruments industry median Graham Number is 1.76. Xvivo Perfusion AB's value of $3.59 is 104.6% above this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #381 out of 400 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Graham Number compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #381 out of 400 companies for Graham Number. This places Xvivo Perfusion AB in the lower half of its industry. The industry median Graham Number is 1.76. Xvivo Perfusion AB's value of $3.59 is 104.6% above this benchmark. Historically, Xvivo Perfusion AB's own Graham Number has ranged from 6.01 to 70.19 over the past decade. While the company's 10-year median is 12.84 vs. the industry median of 1.76, Xvivo Perfusion AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Medical Devices & Instruments company?
The median Graham Number among Medical Devices & Instruments companies is 1.76, based on 400 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current Graham Number of $3.59 is 104.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median Graham Number is 1.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current Graham Number is $3.59, which is 72% below median its own 10-year median of 12.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $42.07, compared to a current price of $29.00 — trading 31.1% below its estimated fair value. The current Graham Number is $3.59, which is 72% below median its 10-year median of 12.84 and 104.6% above the Medical Devices & Instruments industry median of 1.76. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Graham Number is $3.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $29.00 is trading 31.1% below its estimated GF Value™ of $42.07.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
Graham Number: $3.59 (72% below median its 10-year median of 12.84)
GF Value™: $42.07 vs. price of $29.00 (31.1% below fair value)
Industry Position: 104.6% above the Medical Devices & Instruments median (#381 of 400)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score
Get the complete analysis for XVIPF
Graham Number is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
